The latest price target for Aridis Pharmaceuticals (OTCQB:ARDS) was reported by HC Wainwright & Co. on November 6, 2023. The analyst firm set a price target for $2.00 expecting ARDS to rise to within 12 months (a possible 2798.55% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Aridis Pharmaceuticals (OTCQB:ARDS) was provided by HC Wainwright & Co., and Aridis Pharmaceuticals reiterated their buy rating.

There is no last upgrade for Aridis Pharmaceuticals

The last downgrade for Aridis Pharmaceuticals Inc happened on August 16, 2022 when Maxim Group changed their price target from N/A to N/A for Aridis Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aridis Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aridis Pharmaceuticals was filed on November 6, 2023 so you should expect the next rating to be made available sometime around November 6, 2024.

While ratings are subjective and will change, the latest Aridis Pharmaceuticals (ARDS) rating was a reiterated with a price target of $0.00 to $2.00. The current price Aridis Pharmaceuticals (ARDS) is trading at is $0.07, which is within the analyst’s predicted range.